Clinical Trials Logo

Clinical Trial Summary

We believe that blocking of the Greater Splanchnic Nerve (GSN) will stop Sympathetic Nervous System (SNS) activity from reaching the splanchnic vessels and result in a redistribution of blood volume back into the splanchnic reservoir, which will result in reduction of central venous, pulmonary and right and left heart pressures. For patients having Heart Failure With Preserved Ejection Fraction (HFpEF) we expect these changes to improve dyspnea and capacity to exercise, improve quality of life, increased diuretic responsiveness, Furthermore, the expected benefits of unloading the central venous and arterial system through GSN ablation should improve hemodynamic control and lessen the incidence and severity of acute decompensations leading to reduced re-hospitalizations and associated healthcare costs. This has the potential for significant social and healthcare impact.


Clinical Trial Description

Heart failure (HF) is a major and growing public health problem with more than 5 million identified cases and an incidence of over 600,000 new cases per year in the United States alone. Close to 1 million hospitalizations for heart failure occur annually, accounting for over 6.5 million hospital days and a substantial portion of the estimated $37.2 billion that is spent each year on HF in the United States. Nearly half of all patients with HF have so called heart failure with preserved ejection fraction (HFpEF). The 5-year mortality for HFpEF has been reported as high as 50-65%. There are no current evidenced-based HFpEF therapies beyond diuretic control for fluid overload and standard treatments for comorbidities, making HFpEF an exemplary example of an unmet medical need of a rising societal burden and that is associated with substantial morbidity and mortality.

In HFpEF, sympathetic nervous system (SNS) hyperactivity results in decreased splanchnic capacitance causing more blood to be distributed into the central venous and arterial system. This leads to increase central venous pressure, pulmonary pressures and right/left heart pressures, which ultimately results in: congestions, diuretic resistance, acute decompensations leading to rehospitalization, dyspnea and intolerance to even mild exercise, and progressive diastolic dysfunction.

We believe that blocking of the GSN will stop SNS activity from reaching the splanchnic vessels and result in a redistribution of blood volume back into the splanchnic reservoir, which will result in reduction of central venous, pulmonary and right and left heart pressures. For patients with HFpEF we expect these changes to improve dyspnea and capacity to exercise, improve quality of life, increased diuretic responsiveness, Furthermore, the expected benefits of unloading the central venous and arterial system through GSN ablation should improve hemodynamic control and lessen the incidence and severity of acute decompensations leading to reduced re-hospitalizations and associated healthcare costs. This has the potential for significant social and healthcare impact.

Sympathetic and parasympathetic innervation is carried to the upper abdominal viscera by the GSN, lesser splanchnic nerve (LSN) and least splanchnic nerve (LTSN), which originate from the 5th to 8th, 9th to 10th, and 11th thoracic ganglia, respectively. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03715543
Study type Interventional
Source Noblewell
Contact
Status Completed
Phase N/A
Start date August 1, 2016
Completion date June 30, 2019

See also
  Status Clinical Trial Phase
Recruiting NCT05839730 - Fast Induced Remodeling in Heart Failure With Preserved Ejection Fraction N/A
Recruiting NCT05095688 - Relationship Between Adipose Tissue Distribution and Arterial Stiffness in HFpEF
Recruiting NCT05676684 - Dapagliflozin, Spironolactone or Both for HFpEF Phase 2/Phase 3
Recruiting NCT04153136 - Effects of Sacubitril/Valsartan on Subclinical Heart Failure in HIV (The ENCHANTMENT HIV Study) Phase 2
Recruiting NCT06114498 - Hospital Register of Decompensated Heart Failure With Preserved Ejection Fraction
Recruiting NCT05715697 - Renal Denervation in Patients With Chronic Heart Failure With Preserved Ejection Fraction N/A
Recruiting NCT04745013 - PeRsonalIzed remOtely Guided Preventive exeRcIse Therapy for a healThY Heart N/A
Completed NCT05586828 - A Single-center Retrospective Cohort Study to Explore the Prognostic Significance of CONUT in Elderly CAD Patients With HFpEFand Compare CONUT With Other Objective Nutritional Indices.
Completed NCT05126836 - Cilostazol for HFpEF Phase 2
Recruiting NCT04594499 - The Relationship Between Pericardial Fat Thickness and Arterial Stiffness in HFpEF Patients
Active, not recruiting NCT05204238 - Follow Up of acuTe Heart failUre: a pRospective Echocardiographic and Clinical Study (FUTURE)
Completed NCT04535726 - The Relationship Between Blood Pressure and Arterial Stiffness in HFpEF Patients With Different Levels of Obesity
Recruiting NCT03550235 - Exploration of Dyspnea at Non-high Brain Natriuretic Peptide (BNP)
Completed NCT04633460 - Acute Effects of Exogenous Ketone Ester Administration in Heart Failure Phase 2
Completed NCT06228807 - Clinical Characteristics and Predictors of Adverse Outcomes in HFpEF
Active, not recruiting NCT05284617 - Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF Phase 2
Recruiting NCT05562063 - Sotagliflozin in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients Phase 4
Recruiting NCT06027307 - Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation Phase 3
Recruiting NCT05582044 - Exercise Lower-body Negative Pressure in Heart Failure With Preserved Ejection Fraction N/A
Withdrawn NCT05322616 - Single-Ascending Dose Study of JK07 in Subjects With HFpEF Phase 1